Top

International Urology and Nephrology

Published in:

21-06-2023 | Diabetic Nephropathy | Nephrology - Original Paper

CircLARP1B promotes pyroptosis of high glucose-induced renal mesangial cells by regulating the miR-578/TLR4 axis

Authors: Yan Du, Yu Feng, Yu Cai, Chang Tian

Published in: International Urology and Nephrology | Issue 1/2024

Abstract

Background

Diabetic nephropathy (DN) is a main cause of end-stage renal disease with high mortality. Circular RNAs (circRNAs) are associated with the pathogenesis of DN. This study aimed to explore the role of circLARP1B in DN.

Methods

The levels of circLARP1B, miR-578, TLR4 in DN and high glucose (HG)-treated cells using quantitative real-time PCR. Their relationship was analyzed using dual-luciferase reporter assay. The biological behaviors were assessed by MTT assay, EDU assay, flow cytometry, ELISA, and western blot.

Results

The results indicated that circLARP1B and TLR4 were highly expressed, and miR-578 was low expressed in patients with DN and HG-induced cells. Knockdown of circLARP1B promoted the proliferation and cell cycle, and inhibited pyroptosis and inflammation of HG-induced cells. CircLARP1B is a sponge of miR-578, which targets TLR4. Rescue experiments showed that inhibition of miR-578 reversed the effects of circLARP1B knockdown, while TLR4 reversed the effects of miR-578.

Conclusion

CircLARP1B/miR-578/TLR4 axis suppressed the proliferation, blocked cell cycle at the G0-G1 phase, promoted pyroptosis, and inflammatory factor release of renal mesangial cells induced by HG. The findings suggested that circLARP1B may be a target for the treatment of DN.

Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152. https://doi.org/10.1042/CS20120198CrossRefPubMed

Lu Z, Liu N, Wang F (2017) Epigenetic regulations in diabetic nephropathy. J Diabetes Res 2017:7805058. https://doi.org/10.1155/2017/7805058CrossRefPubMedPubMedCentral

Valencia WM, Florez H (2017) How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ 356:i6505. https://doi.org/10.1136/bmj.i6505CrossRefPubMed

Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3–15. https://doi.org/10.1111/dom.14007CrossRefPubMed

Lv J, Wu Y, Mai Y, Bu S (2020) Noncoding RNAs in diabetic nephropathy: pathogenesis, biomarkers, and therapy. J Diabetes Res 2020:3960857. https://doi.org/10.1155/2020/3960857CrossRefPubMedPubMedCentral

van Zonneveld AJ, Kölling M, Bijkerk R, Lorenzen JM (2021) Circular RNAs in kidney disease and cancer. Nat Rev Nephrol 17(12):814–826. https://doi.org/10.1038/s41581-021-00465-9CrossRefPubMed

Peng F, Gong W, Li S, Yin B, Zhao C, Liu W, Chen X, Luo C, Huang Q, Chen T, Sun L, Fang S, Zhou W, Li Z, Long H (2021) circRNA_010383 acts as a sponge for miR-135a, and its downregulated expression contributes to renal fibrosis in diabetic nephropathy. Diabetes 70(2):603–615. https://doi.org/10.2337/db20-0203CrossRefPubMed

Yao T, Zha D, Hu C, Wu X (2020) Circ_0000285 promotes podocyte injury through sponging miR-654–3p and activating MAPK6 in diabetic nephropathy. Gene 747:144661. https://doi.org/10.1016/j.gene.2020.144661CrossRefPubMed

Wang Y, Qi Y, Ji T, Tang B, Li X, Zheng P, Bai S (2021) Circ_LARP4 regulates high glucose-induced cell proliferation, apoptosis, and fibrosis in mouse mesangial cells. Gene 765:145114. https://doi.org/10.1016/j.gene.2020.145114CrossRefPubMed

10.

Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, Guerrero-Hue M, García-Caballero C, Vázquez-Carballo C, Mas S, Sanz AB, Herencia C, Mezzano S, Gómez-Guerrero C, Moreno JA, Egido J (2020) Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci 21(11):3798. https://doi.org/10.3390/ijms21113798CrossRefPubMedPubMedCentral

11.

Al Mamun A, Ara Mimi A, Wu Y, Zaeem M, Abdul Aziz M, Aktar Suchi S, Alyafeai E, Munir F, Xiao J (2021) Pyroptosis in diabetic nephropathy. Clin Chim Acta 523:131–143. https://doi.org/10.1016/j.cca.2021.09.003CrossRefPubMed

12.

Wen S, Li S, Li L, Fan Q (2020) circACTR2: a novel mechanism regulating high glucose-induced fibrosis in renal tubular cells via pyroptosis. Biol Pharm Bull 43(3):558–564. https://doi.org/10.1248/bpb.b19-00901CrossRefPubMed

13.

Maezawa Y, Takemoto M, Yokote K (2015) Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig 6(1):3–15. https://doi.org/10.1111/jdi.12255CrossRefPubMed

14.

Manda G, Checherita AI, Comanescu MV, Hinescu ME (2015) Redox signaling in diabetic nephropathy: hypertrophy versus death choices in mesangial cells and podocytes. Mediators Inflamm 2015:604208. https://doi.org/10.1155/2015/604208CrossRefPubMedPubMedCentral

15.

Tung CW, Hsu YC, Shih YH, Chang PJ, Lin CL (2018) Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology (Carlton) 23(Suppl 4):32–37. https://doi.org/10.1111/nep.13451CrossRefPubMed

16.

Jin J, Sun H, Shi C, Yang H, Wu Y, Li W, Dong YH, Cai L, Meng XM (2020) Circular RNA in renal diseases. J Cell Mol Med 24(12):6523–6533. https://doi.org/10.1111/jcmm.15295CrossRefPubMedPubMedCentral

17.

Zhu S, Chen Y, Ye H, Wang B, Lan X, Wang H, Ding S, He X (2022) Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma. Ann Hepatol 27(2):100678. https://doi.org/10.1016/j.aohep.2022.100678CrossRefPubMed

18.

Wang L, Hou S, Li J, Tian T, Hu R, Yu N (2022) Circular RNA circ-LARP1B contributes to cutaneous squamous cell carcinoma progression by targeting microRNA-515-5p/TPX2 microtubule nucleation factor axis. Bioengineered 13(1):1209–1223. https://doi.org/10.1080/21655979.2021.2019172CrossRefPubMedPubMedCentral

19.

Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495(7441):384–388. https://doi.org/10.1038/nature11993CrossRefPubMed

20.

Chen Z, Wang F, Xiong Y, Wang N, Gu Y, Qiu X (2020) CircZFR functions as a sponge of miR-578 to promote breast cancer progression by regulating HIF1A expression. Cancer Cell Int 20:400. https://doi.org/10.1186/s12935-020-01492-5CrossRefPubMedPubMedCentral

21.

Wang M, Ma M, Yang Y, Li C, Wang Y, Sun X, Wang M, Sun Y, Jiao W (2021) Overexpression of hsa_circ_0008274 inhibited the progression of lung adenocarcinoma by regulating HMGA2 via sponging miR-578. Thorac Cancer 12(16):2258–2264. https://doi.org/10.1111/1759-7714.14059CrossRefPubMedPubMedCentral

22.

Yan P, Sun C, Luan L, Han J, Qu Y, Zhou C, Xu D (2022) Hsa_circ_0134111 promotes intervertebral disc degeneration via sponging miR-578. Cell Death Discov 8(1):55. https://doi.org/10.1038/s41420-022-00856-2CrossRefPubMedPubMedCentral

23.

Gao Q, Zheng Y, Wang H, Hou L, Hu X (2022) circSTRN3 aggravates sepsis-induced acute kidney injury by regulating miR-578/ toll like receptor 4 axis. Bioengineered 13(5):11388–11401. https://doi.org/10.1080/21655979.2022.2061293CrossRefPubMedPubMedCentral

24.

Zhou RM, Shi LJ, Shan K, Sun YN, Wang SS, Zhang SJ, Li XM, Jiang Q, Yan B, Zhao C (2020) Circular RNAZBTB44 regulates the development of choroidal neovascularization. Theranostics 10(7):3293–3307. https://doi.org/10.7150/thno.39488

25.

Regulatory Network in Diabetic Nephropathy. J Healthc Eng. 2021; 2021:8161701. doi: https://doi.org/10.1155/2021/8161701

26.

Linde A, Mosier D, Blecha F, Melgarejo T (2007) Innate immunity and inflammation–new frontiers in comparative cardiovascular pathology. Cardiovasc Res 73(1):26–36. https://doi.org/10.1016/j.cardiores.2006.08.009CrossRefPubMed

27.

Sheu JJ, Chang LT, Chiang CH, Youssef AA, Wu CJ, Lee FY, Yip HK (2008) Prognostic value of activated toll-like receptor-4 in monocytes following acute myocardial infarction. Int Heart J 49(1):1–11. https://doi.org/10.1536/ihj.49.1CrossRefPubMed

28.

Rocha DM, Caldas AP, Oliveira LL, Bressan J, Hermsdorff HH (2016) Saturated fatty acids trigger TLR4-mediated inflammatory response. Atherosclerosis 244:211–215. https://doi.org/10.1016/j.atherosclerosis.2015.11.015CrossRefPubMed

29.

Wu Y, Zhao Y, Yang HZ, Wang YJ, Chen Y (2021) HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. Biosci Rep 41(2):BSR20202924. https://doi.org/10.1042/BSR20202924CrossRefPubMedPubMedCentral

30.

Zhu L, Han J, Yuan R, Xue L, Pang W (2018) Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res 51(1):9. https://doi.org/10.1186/s40659-018-0157-8CrossRefPubMedPubMedCentral

Title: CircLARP1B promotes pyroptosis of high glucose-induced renal mesangial cells by regulating the miR-578/TLR4 axis
Authors: Yan Du
Yu Feng
Yu Cai
Chang Tian
Publication date: 21-06-2023
Publisher: Springer Netherlands
Keyword: Diabetic Nephropathy
Published in: International Urology and Nephrology / Issue 1/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-023-03672-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

A matched-analysis on short-term and long-term (up to 5 years of follow-up) urinary incontinence outcomes after robot-assisted radical prostatectomy with and without anterior and posterior reconstruction: data on 1358 patients

LAD pyeloplasty versus open in UPJO with poorly functioning kidney in pediatrics: response to editors

Exploration of patients’ preference for modalities of care among peritoneal dialysis patients in Singapore: a single-center experience

Prediction of acute kidney injury in patients with liver cirrhosis using machine learning models: evidence from the MIMIC-III and MIMIC-IV

Reply to comment on “Hyperuricemia may be associated with muscle wellness in older adults”

Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials